References
- Schlagenhauf P, Weld L, Goorhuis A, et al. Travel-associated infection presenting in Europe (2008-12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation. Lancet Infect Dis. 2015;15:55–64.
- Medlock JM, Leach SA. Effect of climate change on vector-borne disease risk in the UK. Lancet Infect Dis. 2015;15:721–730.
- Yang GJ, Liu L, Zhu HR, et al. China’s sustained drive to eliminate neglected tropical diseases. Lancet Infect Dis. 2014;14:881–892.
- Cabezas-Cruz A, Mateos-Hernández L, Pérez-Cruz M, et al. Regulation of the immune response to α-Gal and vector-borne diseases. Trends Parasitol. 2015;31:470–476.
- Soares MP, Yilmaz B. Microbiota control of malaria transmission. Trends Parasitol. 2016;32:120–130.
- Yilmaz B, Portugal S, Tran TM, et al. Gut microbiota elicits a protective immune response against malaria transmission. Cell. 2014;159:1277–1289.
- Hütter J, Lepenies B. Carbohydrate-based vaccines: an overview. Methods Mol Biol. 2015;1331:1–10.
- Cabezas-Cruz A, Valdés J, De La Fuente J. Cancer research meets tick vectors for infectious diseases. Lancet Infect Dis. 2014;14:916–917.
- Ngwa CJ, Pradel G. Coming soon: probiotics-based malaria vaccines. Trends Parasitol. 2015;31:2–4.
- Kumar H, Salminen S, Verhagen H, et al. Novel probiotics and prebiotics: road to the market. Curr Opin Biotechnol. 2015;32:99–103.
- Manuzak JA, Hensley-McBain T, Zevin AS, et al. Enhancement of microbiota in healthy macaques results in beneficial modulation of mucosal and systemic immune function. J Immunol. 2016;196:2401–2409.
- Czaplewski L, Bax R, Clokie M, et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis. 2016;16:239–251.
- Hani U, Shivakumar HG, Vaghela R, et al. Candidiasis: a fungal infection–current challenges and progress in prevention and treatment. Infect Disord Drug Targets. 2015;15:42–52.
- Ruggiero P. Use of probiotics in the fight against Helicobacter pylori. World J Gastrointest Pathophysiol. 2014;5:384–391.
- Moreira GM, Telmo Pde L, Mendonça M, et al. Human toxocariasis: current advances in diagnostics, treatment, and interventions. Trends Parasitol. 2014;30:456–464.
- Mangold A, Hercher D, Hlavin G, et al. Anti-alpha-Gal antibody titres remain unaffected by the consumption of fermented milk containing Lactobacillus casei in healthy adults. Int J Food Sci Nutr. 2012;63:278–282.
- Dahl K, Kirkeby S, d’Apice AF, et al. The bacterial flora of alpha-Gal knockout mice express the alpha-Gal epitope comparable to wild type mice. Transpl Immunol. 2005;14:9–16.
- Galili U, Mandrell RE, Hamadeh RM, et al. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun. 1988;56:1730–1737.
- De Kivit S, Tobin MC, Forsyth CB, et al. Regulation of intestinal immune responses through TLR activation: implications for pro- and prebiotics. Front Immunol. 2014;5:60.
- Lee J, Mo J-H, Katakura K, et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol. 2006;8:1327–1336.
- Villarino NF, LeCleir GR, Denny JE, et al. Composition of the gut microbiota modulates the severity of malaria. Proc Natl Acad Sci U S A. 2016;113:2235–2240.
- Ramasamy R, Rajakaruna R. Association of malaria with inactivation of alpha1,3-galactosyl transferase in catarrhines. Biochim Biophys Acta. 1997;1360:241–246.